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Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, ItalySummary of the development rates of liver-related complications. However,Chronic infection with the hepatitis B and C virus represents a
major health problem worldwide, as it is estimated that roughly
400 and 200 million people respectively, are infected by each
virus. By deﬁnition, any antiviral therapy that claims to be
effective should have as its ultimate efﬁcacy end point an
improvement in patients’ survival, or at least a reduction in the
development rates of liver-related complications. However, this
is extremely complicated to prove as the natural course of both
viral diseases is extremely slow, requiring decades to evolve in
cirrhosis and even more years to lead to liver complications.
For this reason, clinicians and health authorities have relied on
so called surrogate end points to assess the efﬁcacy of any ther-
apeutic intervention for viral hepatitis. Obviously, this allows
for standardization in study designs that ultimately translates
into an accelerated time frame for therapeutic drugs as well as
healthcare innovations to enter the viral hepatitis clinical prac-
tice. However, it also calls for demonstration that surrogate end
points in the treatment of patients with chronic hepatitis B or C
are good and reliable markers of long-term efﬁcacy.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Introduction
Chronic infection with the hepatitis B (HBV) and C virus (HCV)
represents a major health problem worldwide, as it is estimated
that roughly 400 and 200 million people respectively, are
infected by each virus [1]. These people are at increased risk of
developing cirrhosis, hepatocellular carcinoma (HCC), liver
decompensation, and esophageal variceal bleeding, that ulti-
mately explains why HBV and HCV infection is the current lead-
ing cause of liver-related death and the main indication for liver
transplantation in developed countries [2]. By deﬁnition, any
anti-HBV or anti-HCV therapy that claims to be effective should
have as its ultimate efﬁcacy end point an improvement in
patients’ survival through the prevention, or at least reduction,Journal of Hepatology 20
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the dramatic and life threatening complications of HBV and HCV
infection are likely to occur in most patients many decades after
viral infection and many years after diagnosis of hepatitis. In the-
ory, in patients with HBV or HCV chronic infection, a study
designed to assess the impact of a speciﬁc therapeutic regimen,
should therefore not only follow-up patients for impossibly long
periods of time after treatment completion, but also exclude
treatment failure patients from any form of retreatment whilst
maintaining them on clinical observation, a feat that is obviously
impossible and unethical. Clinicians, health authorities, and phar-
maceutical companies have therefore relied on so called surro-
gate end points to assess the efﬁcacy of any therapeutic
intervention for viral hepatitis [3]. Obviously, this allows for an
accelerated clinical/scientiﬁc progress in the hepatology ﬁeld, as
drugs as well as healthcare innovations can more rapidly be
introduced in everyday clinical practice, however, it also calls
for demonstration that surrogate end points in the treatment of
patients with chronic hepatitis B or C are good and reliable mark-
ers of efﬁcacy.Deﬁning antiviral treatment efﬁcacy end points
HBV and HCV are characterized by peculiar biological and clinical
characteristics, but probably the most important difference
between these viruses is that HCV can be eradicated, while HBV
remains detectable in the liver either integrated into the host
DNA or as covalently closed circular DNA (cccDNA), the template
for transcription of viral RNA [4,5]. For this reason, any anti-HCV
regimen is aimed at persistent viral eradication, while anti-HBV
regimens are aimed at sustained suppression of viral replication.
Currently, in HCV patients, viral eradication is deﬁned as a sus-
tained virological response (SVR), which means serum HCV
RNA undetectability 24 weeks after pegylated interferon (PegIFN)
plus ribavirin (RBV) with or without a directly acting antiviral
agent (DAA). This surrogate end point has been shown to reﬂect
persistent serum viral eradication by a large study analyzing
1343 HCV patients followed for a mean time period of 3.9 years
after an SVR to PegIFNa2a plus RBV, as 99.1% of the population
remained persistently serum HCV RNA negative during the fol-
low-up period [6]. The 0.9% rate of HCV-RNA positivity reported
in this study is most likely to be caused by patients reacquiring12 vol. 57 j 1326–1335
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HCV infection due to concomitant risk factors, more than by a late
post-treatment relapse. Indeed, studies analyzing HCV RNA in the
liver and in peripheral blood mononuclear cells have shown an
SVR to be associated with HCV RNA elimination in these body
districts, too [7]. Recently, both the Federal Drug Administration
(FDA) and the European Medical Agency (EMA) have shortened
the post-treatment follow-up period necessary to deﬁne an SVR
by introducing the so called SVR12, deﬁned as HCV RNA unde-
tectability 12 weeks following PegIFN/RBV. This change is sup-
ported by the results of two studies in HCV patients, one in
HIV/HCV co-infected patients and one in HCV post-transplant
patients showing that 827 of 828 (99.9%) patients who had an
SVR12 achieved an SVR24 [8–11].
In HBV patients, the therapeutic end points are a bit more
complex, as chronic hepatitis B is characterized by a hepatitis B
e antigen (HBeAg) positive phase and a HBeAg negative phase.
The HBeAg positive phase usually precedes the HBeAg negative
phase, and is further divided into an immune tolerant phase,
where liver damage is generally mild and non-progressive, and
an immune reactive phase, characterized by elevations of amino-
transferases levels and more rapid progression of liver ﬁbrosis.
The HBeAg negative phase of chronic hepatitis B is associated
with a high risk of progression to advanced ﬁbrosis, cirrhosis
and subsequent liver-related complications. Although in both
HBeAg phases the ideal end point of therapy is sustained HBsAg
loss with or without seroconversion to anti-HBs, as this is associ-
ated with a complete and deﬁnitive remission of the activity of
chronic hepatitis B, this event is quite rare in clinical practice
as only 1–7% of cases achieve it during a 1-year treatment period
[4]. For this reason, in HBeAg-positive patients, durable HBe sero-
conversion is considered a satisfactory end point, while in the
HBeAg-positive patients who do not achieve HBe seroconversion,
and in all HBeAg-negative patients, a maintained undetectable
HBV DNA level on treatment with nucleos(t)ide analogs (NUC)
or a sustained undetectable HBV DNA level after IFN therapy, is
the desired end point [4].Do therapeutic end points modify the natural history of HBV
infection?
Probably
Since serum HBV DNA undetectability is the prerequisite to
deﬁne HBeAg and HBsAg seroconversion as an end point of
anti-HBV therapy, suppression of HBV DNA is the most reliable
response predictor of any HBV therapy. This notwithstanding, it
is still debated whether persistent undetectability of serum HBV
DNA, by highly sensitive and speciﬁc PCR based assays, really
stands for a surrogate of a cure. In a minority of patients only,
serum HBV DNA undetectability will deﬁnitively mirror HBV
eradication, as clearly demonstrated by the almost universal
recurrence of detectable viremia following withdrawal of antivi-
ral regimens [4]. Working against the generalisability of a viro-
logical response in HBV patients as an index of treatment
efﬁcacy is also the observation that HBV DNA undetectability
is restricted to long-term administration of third generation
direct antivirals only, i.e., entecavir or tenofovir, since ﬁrst (lam-
ivudine) and second generation antivirals (adefovir, telbivudine)
have time limited efﬁcacy as a consequence of drug resistanceJournal of Hepatology 2012developing in up to 80% of lamivudine-treated patients and in
29% of the adefovir treated patients [4]. Generalisability of a
virological response in HBV patients is also limited by a differ-
ent HBV DNA cut-off (<2000 IU/ml) for patients responding to
PegIFN, which is a therapeutic option for a niche of patients
only.
In weighing the long-term beneﬁts of antiviral therapy in
HBV, special consideration should be given to the evolution of
serum HBV DNA assays, which have signiﬁcantly improved in
sensitivity over time, as well as the new therapeutic options that
shifted from interferon as the only option with limited applicabil-
ity, to NUC that have been successfully employed in patients with
a variety of clinical conditions, including liver failure. Not to men-
tion the evolution of oral analogs in terms of potency, from low
genetic barrier and moderately potent drugs such as lamivudine,
adefovir and telbivudine which kept physicians busy trying to put
viral replication under control, to entecavir and tenofovir, which
are more user friendly, providing full suppression of viral replica-
tion in >95% of the patients over 5 years of monotherapy [4]
(Tables 1 and 2). Along the same line, treatment end points have
evolved too, considering that in the interferon era, serological
events, such as HBeAg and HBsAg seroconversion, were ‘‘the’’
end points of treatment, whereas nowadays undetectable HBV
DNA by RT-PCR (<10–15 IU/ml) has become the standard of care
to guide treatment with oral analogs. Further attenuating the
importance of serological end points is not only their dependence
on undetectable HBV DNA, but also the fact that end points, such
as interferon-induced HBeAg seroconversion, are not durable in
all patients and are not granting HBV suppression [12]. Even
the clinical relevance of HBsAg seroconversion, the proxy to a
cure, is now challenged by the new therapeutic algorithms in
patients fully suppressed by NUC, in whom HBeAg and HBsAg
seroconversion is now considered as a stopping rule rather than
as ‘‘true’’ end point of therapy. Finally, last but not least, on-treat-
ment quantiﬁcation of serum HBsAg at week 12 has been shown
to accurately predict non-response to Peg-IFN in both HBeAg
positive and negative patients, with the aim to identify patients
to be early withdrawn from interferon and to switch to long-term
NUC therapy [4].
HBeAg seroconversion
Spontaneous HBeAg seroconversion occurs in 2–15% of chronic
carriers depending on age, ALT levels, and HBV genotype [13], fre-
quently heralding a decreased risk of cirrhosis and HCC, particu-
larly when it occurs before the age of 30 [14]. For decades, HBeAg
seroconversion has been the standard of care end point for inter-
feron-treated HBeAg positive patients worldwide, due to its strict
association not only with a decline of viral replication, but also
with a clinical and histological remission of liver disease and
increase in survival [15]. Approximately one third of all patients
with active hepatitis will achieve HBeAg seroconversion follow-
ing PegIFN therapy [4], with higher rates in those with a baseline
HBV DNA below 7 log IU/ml, ALT levels >2–5 time ULN, genotype
A and B of HBV, in the absence of basal core promoter and precore
mutations (Table 1). In these patients, seroconversion is
associated with a lower likelihood of progression to cirrhosis,
development of HCC and liver-related mortality compared to
non-responders or untreated patients [16], but the beneﬁt of
therapy are often challenged by limited durability of HBeAg sero-
conversion heralding the risk of evolving to HBeAg negativevol. 57 j 1326–1335 1327
Table 1. Rates of virological and serological responses in patients with CHB
treated with PegIFN, ETV or TDF. Responses were assessed at 6 months








HBV-DNA <60-80 IU/ml 7-14 67 76
ALT normalization 32-41 68 68
HBeAg seroconversion 32-29 21 21
HBsAg loss 3-7 2 3
HBeAg negative CHB
HBV-DNA <60-80 IU/ml 19 90 93
ALT normalization 59 78 76
HBsAg loss 4 0 0
Table 2. Rates of virological and serological responses in patients with CHB






HBV-DNA <60-80 IU/ml 94 96
ALT normalization 80 69
HBeAg seroconversion 54* 40
HBsAg loss 6.4* 11
Anti-HBs seroconversion n.a.* 8
HBeAg negative CHB
HBV-DNA <60-80 IU/ml 95** 99
ALT normalization 59** 85
HBsAg loss n.a.** <1
Anti-HBs seroconversion n.a.** <1
⁄For ETV, only selected patients continued therapy for 5 years.
⁄⁄For ETV, 3-year data available.
Reviewchronic hepatitis B [12]. The latter risk is only exceptionally seen
in serum-converters with HBV DNA levels persistently below
2000 IU/ml, creating the basis for a new deﬁnition of the HBeAg
seroconversion end point, particularly for patients undergoing
third generation NUC therapies that have been associated with
high rates of compliance, adherence and HBeAg seroconversion
(50%) (Table 2). Again, the durability and clinical signiﬁcance of
HBeAg seroconversion in these patients is doubtful since a num-
ber of patients following discontinuation of NUC seroreverted to
HBeAg or developed serum HBeAg negative chronic hepatitis B,
this worrisome ﬁnding, however, needs to be addressed by larger
studies in different geographical areas [17–22].
Thus, HBeAg seroconversion coupled with serum HBV DNA
levels <2000 IU/ml, is a reasonably trustable, but still imperfect,
end point in both treated and untreated patients, whereas serum
HBV DNA undetectability is a key therapeutic end point in the
NUC scenario, where HBeAg seroconversion has been downgraded
to the role of a potential, stopping rule. While HBeAg seropositive
patients with mild to moderate chronic hepatitis B, and persistent
HBV DNA undetectability showed attenuated progression to1328 Journal of Hepatology 2012cirrhosis and related complications, including HCC, there are no
data on overall patients survival.
HBsAg seroclearance and seroconversion
HBsAg seroclearance may spontaneously occur in carriers of inac-
tive HBV infection as well as in patients with chronic active hep-
atitis following a successful virological response to therapy.
Longitudinal studies in Asia clearly demonstrated that undetect-
able serum HBV DNA was the prerequisite to clear HBsAg in more
than 95% of the patients [23]. Spontaneous HBsAg clearance
occurs in less than 2% of the inactive carriers [24], whereas in
responders to interferon-based regimens HBsAg sero-clearance
is largely inﬂuenced by HBeAg status, patient age and underlying
liver disease, ultimately ranging from 0.5% to 2.3% [25,26] (Table
1). The lower seroconversion rates are observed in HBeAg sero-
negative patients and those treated with direct antivirals that
can only indirectly stimulate the immune mediated clearance
of the infected hepatocytes, which is one of the key events in
determining the serum levels of HBsAg (Table 2). Interferon-
based regimens instead, exert a moderate antiviral activity
together with a strong immunostimulatory activity, which accel-
erates the clearance of infected hepatocytes. Differences in the
rates of HBsAg seroclearance following treatment with either
interferon or direct antivirals is also underscored by differences
in the on-treatment decline of serum levels of HBsAg, which
are deﬁnitively quicker and more pronounced following inter-
feron than direct antivirals [27]. Mitigating, however, against
the assumption that HBsAg seroclearance and seroconversion in
all cases stand for a cure of hepatitis B, are studies showing per-
sistence of biologically active cccDNA of HBV in the livers of
HBsAg seronegative individuals, even in subjects carrying the
serum anti-HBs marker of protective immunity against HBV, a
condition deﬁned as occult HBV infection [4]. As a matter of fact,
in a reanalysis of 298 patients in Hong Kong, HCC was found to
develop in a signiﬁcant number of patients from 1 year to more
than 10 years following spontaneous clearance of serum HBsAg,
with higher attack rates in patients over 50, a ﬁnding that led
the authors to speculate on a potential pathogenic role of age-
related factors like advanced liver ﬁbrosis or long term exposure
to the carcinogenic activity of occult HBV, or a combination of
both [28]. Indeed, evidence has cumulated to indicate occult
infection as an established risk factor of HCC in both patients
with an originally pure HBV infection and those with co-morbid-
ities like alcoholic liver disease and chronic hepatitis C [29]. The
fact that spontaneous HBsAg seroconversion is a rare event,
occurring in inactive carriers only, and that treatment-related
HBsAg seroconversion occurs in association with HBV DNA unde-
tectability, supports anti-HBV therapy and HBV DNA undetect-
ability as disease modifying markers of chronic hepatitis B.
Certainly
Studies in cirrhotic patients who are more prone to develop clin-
ical end points like decompensation or HCC, provided evidence
for effective anti-HBV treatment to have a favorable impact on
patients survival by the prevention of liver-related complications.
Long-term suppressive therapy with NUC, in fact, was associated
with histological regression of cirrhosis, prevention of clinical
decompensation, reduction of the incidence rates of liver cancer,
reversal of clinical decompensation, as well as increased listing to
and survival following liver transplantation.vol. 57 j 1326–1335
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Histological regression of cirrhosis
In the face of remission or inactivation of cirrhosis spontane-
ously occurring in HBV carriers, there are recent reports of
histological regression of HBV-related cirrhosis following suc-
cessful anti-HBV treatment. With all the caveats related to the
referral bias of a multicenter registration trial and the post hoc
analysis of relatively sparse cases, Chang and co-workers ﬁrst
documented the histological reversal of cirrhosis in 4 out of 10
cases who met the criteria for efﬁcacy analysis, while they were
in a 3- to 7-year period of sustained virological response to ent-
ecavir [30] However, these results derive from a rather heteroge-
neous cohort composed of 354 HBeAg and 325 anti-HBe
seropositive patients, with different HBV genotypes who were
enrolled in two registration trials of a daily dose of 0.5 mg ent-
ecavir for 3 years (several HBeAg positive patients had also
received lamivudine) and 1 mg in the rollover period of study.
Interestingly, none of the patients enrolled in the study was able
to clear serum HBsAg in the long term. More robust evidence of
cirrhosis reversion was offered by the reanalysis of 96 patients
with cirrhosis, mostly HBeAg negative, enrolled in the rollover
study of the registration trial of tenofovir, who underwent a sec-
ond liver biopsy after 5 years of undetectable serum HBV DNA
by a PCR-based assay with a limit sensitivity of 69 IU/ml [31].
The ﬁndings that 70 (73%) patients had an Ishak staging
decrease of at least 2 points as a consequence of successful anti-
viral therapy, and that 71 (74%) patients had cirrhosis histolog-
ically reversed, support persistent HBV suppression to translate
into signiﬁcant remodeling of the ﬁbrotic matrix and septa,
which accompanies chronic liver cell necro-inﬂammation elic-
ited by HBV replication.
Prevention of liver disease progression
A landmark study in patients with advanced ﬁbrosis (Ishak stage
4–6) from Hong Kong and the Paciﬁc area, provided substantial
evidence on the ability of lamivudine to delay progression of
HBV-related liver disease, as it was cumulatively assessed in
terms of increased Child Pugh score, liver failure or HCC develop-
ment [32]. The study was prematurely interrupted at year 3 of
treatment when the rates of liver disease progression were
shown to differ between arms, subsequently resulting to be
24% in patients on placebo and 9% in those under active treat-
ment (p = 0.001). While the clinical beneﬁts were maintained in
patients with a persistent virological response to lamivudine
only, treatment-related beneﬁts were in part lost in the lamivu-
dine-treated patients who experienced a virological break-
through, following the onset of lamivudine resistance. In these
patients, the incidence rate of clinical end points, including
HCC, was higher (11% vs. 5%) than in the placebo patients at
month 32 (p <0.031). Despite some caveats related to pooling
clinical outcomes with a tumor end point that would require a
separate assessment to guide anticipated interruption of a ran-
domized study, when results had crossed the predeﬁned bound-
ary for showing efﬁcacy, the study by Liaw and co-workers is
universally taken as evidence of antiviral agents being able to
prevent deterioration of chronic hepatitis B, a fact that for ethical
reasons discouraged further controlled studies in the ﬁeld. The
most intriguing ﬁnding of the Hong Kong study was that patients,
despite achieving a virological response to lamivudine, ultimately
developed HCC, which was in fact the only complication arising
in virological responders (Table 3). Other ﬁndings added to the
debate of HCC arising in patients responding long term to NUCs.Journal of Hepatology 2012In a systematic review of studies of nucleos(t)ide analog treat-
ment of patients with HBV, it was clearly deﬁned that HCC was
prevented in patients with chronic hepatitis but not in those with
cirrhosis, and in general in patients that could not achieve com-
plete virological suppression [33]. A recent cohort study from
Greece conﬁrmed that cirrhotic patients long-term responding
to lamivudine remained at risk of liver cancer development
[34]. However, all these studies enrolled patients treated with
lamivudine or rescued with adefovir, i.e., regimens characterized
by limited potency and low to moderate genetic barrier, which
are not any more recommended by International guidelines, to
treat patients with chronic hepatitis B in general, and especially
in patients with compensated cirrhosis [35]. Moreover, the hope
that more potent NUCs, like entecavir and tenofovir, might ﬁnally
prevent liver cancer in responders with cirrhosis, rapidly faded
away when a multicenter study in Italy, in patients with compen-
sated cirrhosis who had persistently undetectable serum
HBVDNA during 4 years of entecavir monotherapy, showed an
annual rate of neoplastic transformation of the liver of approxi-
mately 2.5% [36], that mimics the HCC rates in untreated HBeAg
negative patients in Europe (Table 3).
In an attempt to reconcile these ﬁndings with the optimistic
reports of an histological regression of cirrhosis in the majority
of long-term responders to HBV antivirals, it should be taken into
account that development of HCC in successfully treated patients
with cirrhosis is often the consequence of an extended survival
provided by NUC, preventing clinical decompensation, as it was
the case in the Italian multicenter study. On the other hand,
HBV-related liver carcinogenesis is likely to be promoted by
cellular events that are established early during chronic HBV
infection, independently of the onset of cirrhosis. The Italian mul-
ticentre study clearly documented prevention of jaundice, ascites,
encephalopathy during long-term suppressive therapy in
cirrhotics. Small studies in Asia and Italy showed regression of
esophageal varices in patients with HBV cirrhosis who were suc-
cessfully treated with lamivudine associated or not with adefovir
[37,38] that mimics the reduction of portal hypertension in trea-
ted patients measured through hepatic venous pressure gradient
(HVPG) [39].
Reversal of clinical decompensation and increased survival following
liver transplantation
Clinical decompensation is a major determinant of liver-related
death in both HBeAg positive and negative patients with hepatitis
B-related cirrhosis. This risk is predicted by persistently elevated
levels of serum HBV DNA, independently of the HBeAg status
[15,40,41]. The beneﬁcial impact of antiviral therapy on patient
survival is easy to demonstrate in patients with decompensated
liver disease, where only 20% are alive after 5 years. In a phase
2, double-blind, randomized study in Asia, persistent HBV DNA
suppression by entecavir or tenofovir led to reversal of clinical
decompensation in most patients with decompensated HBV in
terms of improved Child Pugh score (at least 2 points decrease
on average) and MELD score (2 points decreased from baseline)
[42]. A systemic review of the efﬁcacy and safety of different
antivirals in patients with decompensated HBV cirrhosis showed
an approximately threefold higher rate of 1-year transplant-free
survival of patients treated with lamivudine compared to
untreated patients [43]. An additional proof of concept that
HBV DNA suppression may translate into increased survival, is
the observation that patients decompensated following antiviralvol. 57 j 1326–1335 1329
Table 3. HCC rates in NUC-naïve cirrhotic patients long-term treated with NUC.
Author, yr, [Ref.] Study Continent Disease severity NUC Patients HCC/yr (%)
Liaw et al., 2004, [32] RCT Asia Cirrhosis* LAM 211 w/o resistance 1.5
Papatheodoridis et al., 2010, [33] Review Asia/Europe Cirrhotics LAM 81 responders 2.4
Papatheodoridis et al., 2011, [34] R Europe Cirrhotics LAM 62 responders 2.5
Kurokawa et al., 2012, [35] R Japan Cirrhotics LAM 42 responders 2.8
Lampertico et al., 2011, [36] CP Europe Cirrhotics ETV 164 2.5
RCT, randomized controlled trial; R, retrospective study; CP, cohort prospective study.
⁄Bridging ﬁbrosis and cirrhosis.
Reviewresistance to ﬁrst or second generation anti-HBV analogs, while
being listed to liver transplant, and were successfully rescued
with third generation analogs [44,45]. Tempering the growing
optimism on the efﬁcacy of these new analogs, was the report
of approximately 20% of these severely ill patients with clinical
decompensation who died within the ﬁrst 6 months of therapy
despite full suppression of viral replication or developed HCC
during the ﬁrst 2 years of therapy. This notwithstanding, NUC-
related HBV DNA suppression and reversal of clinical decompen-
sation accounted for the signiﬁcant increase in listing patients
with end-stage HBV for liver transplantation, worldwide. In Eur-
ope, between 1988 and 2007, 14,717 patients with viral cirrhosis
received a liver graft, including 3627 patients with HBV alone
(25%), 1109 with HBV/HDV (7%), 135 with HBV/HCV/HDV (1%),
and 535 with HBV/HCV (4%), an overall 37% of patients requiring
anti-HBV treatment and/or prophylaxis. While the highest rates
of survival were observed in patients with end-stage HDV (90%
at year 10), the aggregated survival of patients with HBV was
greater than 70%, compared to HCV patients whose survival
was around 60% [46]. Owing to the fact that the above cited
pooled outcomes of liver transplantation in Europe cross two
decades of clinical activity with anti-HBV therapy and prophy-
laxis of increasing efﬁcacy and safety, the aggregate ﬁgures of
survival of HBV recipients might underestimate the current suc-
cess rates of liver transplantation in patients with end-stage HBV.
In the reanalysis of 74 patients, with HCC and persistently sup-
pressed serum HBV DNA by NUC, who consecutively received a
liver graft in Milan, the 5-year survival was 89% with a 6% rate
of tumor recurrence almost exclusively occurring in patients
who were transplanted beyond the Milan criteria [47]. Though
a chasm still exists in terms of disease severity between patients
enrolled in trials and patient seen in ﬁeld practice, it is really
encouraging that the rates of HBV suppression, achieved in every-
day clinical practice with third generation NUC, look very similar
to those achieved in registration trials [48].Do therapeutic end points modify the natural history of HCV
infection?
Probably
Although the ultimate aimof anti-HCV therapy in patientswithout
cirrhosis should be the prevention of liver-relatedmortality, this is
a nearly impossible feat for various reasons. First of all, epidemio-
logical studies in Europe and Australia have shown that mortality
for non-liver-related reasons is the main death cause in HCV
patients with a threefold higher rate compared to liver-related1330 Journal of Hepatology 2012deaths [49,50]. Secondly, in HCV patients, the occurrence of liver-
related complications leading to death requires the development
of cirrhosis in the overwhelming majority of the cases. Cirrhosis
determines a structural and vascular remodeling of the liver that
leads to the development of portal hypertension and its clinical
sequelae (ascites, variceal bleeding), and although experimental
evidence supporting a direct oncogenic role ofHCVexists, cirrhosis
is also the main risk factor for HCC development [51]. This implies
that to assess the beneﬁt of an SVR on mortality rates treatment
failure patients should be kept under observation until they
develop cirrhosis, given that the time to progression to cirrhosis
is extremely variable at the individual patient level but usually
requires decades, it is clear why such a study cannot be designed.
However, we do have indirect evidence that HCV has a nega-
tive impact on survival in patients without cirrhosis and that viral
clearance has clinical beneﬁts also in terms of patients survival.
In the above mentioned epidemiological studies from Europe
and Australia, although liver-related mortality was not the main
cause of death among HCV patients, still patients with HCV infec-
tion were more likely to die of liver-related death than those not
HCV infected. Amin and colleagues in Australia found that among
75,834 patients with HCV infection the mortality rate for liver
reasons was 16.9 times higher than that of the general population
matched by age and sex [50]. Even more interestingly, Omland
et al., when analyzing 6292 patients with anti-HCV antibodies,
37% of whom had cleared the virus either spontaneously or fol-
lowing antiviral treatment, found that the 8-year liver-related
death rate in chronic HCV patients was 5.5% compared to 2% in
non-viremic patients, effectively proving that not only HCV infec-
tion increases liver-related mortality, but also that spontaneous
or treatment-induced clearance can have a positive impact on
these ﬁgures [49].
On the same page, a recent large study by the Veterans Affair
health system in the US, analyzing 16,864 HCV patients treated
with PegIFN and RBV, who were followed-up for a median period
of 3.8 years, found SVR to be associated with a reduced risk of all-
cause mortality (Odds Ratio: 0.7) [52]. Even if the cohort analyzed
by Backus et al. had some peculiar features that might not reﬂect
the typical European HCV population (20% had diabetes, 13% cor-
onary artery disease, mean body mass index: 29) and unfortu-
nately the study design could not provide data on the reasons
for death, still it is the ﬁrst prospective demonstration of a sur-
vival beneﬁt associated with an SVR.
Studies analyzing post-SVR liver histology provide further
support to the claim that HCV clearance in patients without cir-
rhosis has clinical beneﬁts, indeed between 57% and 100% show
improved inﬂammation when compared to pre-therapy histolog-
ical ﬁndings and between 0% and 100% show a reduction in thevol. 57 j 1326–1335
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semi-quantitative score of liver ﬁbrosis, providing evidence that
an SVR prevents the progression to cirrhosis [53].
Key Points 
• In HCV patients with cirrhosis the achievement of an 
SVR reduces the rates of liver related complications, 
may lead to cirrhosis regression and improves survival. 
In patients without cirrhosis an SVR prevents disease 
progression while protecting from the development of 
extra-hepatic manifestations of HCV
• Although maintained HBV DNA suppression is rarely 
associated with HBV clearance, it results in reduced 
rates of liver complications. Preliminary data show that 
following long-term HBV DNA suppression
• Maintained HBV DNA suppression does not completely 
abrogate the risk of HCC in patients with pre-existing 
cirrhosis
• 
anti-HBV regimens as seen in clinical trials, and 
effectiveness of both regimens in real life clinical 
practice. This is attributable to under-diagnosis of 
the diseases, lack of referral to liver specialists, poor 
inadequate adherence to current HBV regimens
some patients may also benefit from cirrhosis regression
There is a gap between efficacy of anti-HCV and
tolerability profile of current anti-HCV regimens and
A secondary aim of anti-HCV treatment is to prevent the extra-
hepatic manifestations of the virus [54]. HCV is known to lead
to the production of cryoglobulins through B-lymphocyte cell
activation in roughly 40% of the infected patients, with 20–
30% of these patients developing the cryoglobulinemic syn-
drome characterized by purpura, arthralgias, and weakness. In
some cases cryoglobulinemia may lead to a more serious sys-
temic vasculitis characterized by neurological and/or renal
involvement [55]. HCV has also been shown to interfere with li-
pid and glucose metabolism leading to liver steatosis, develop-
ment of insulin resistance, increased incidence of diabetes and
carotid atherosclerosis [56–60]. HCV can also impair kidney
function by immune-mediated damage, determine cognitive
dysfunction through central nervous system involvement, and
activate B lymphocytes leading in some cases to the develop-
ment of non-Hodgkin’s lymphoma [61–63]. Several lines of evi-
dence show that an SVR is associated with improvement or
prevention of many of these conditions (Table 4) [64–67]. Most
importantly, an SVR has been shown to be associated with re-
duced incidence of non-Hodgkin’s lymphoma in a large study
in Japan, where, during a 15-year follow-up period, none of
the 1048 SVR patients developed lymphoma compared to
2.56% of the 2161 patients with persistent infection, hence fur-
ther strengthening the positive impact of an SVR in HCV
patients.
All in all, even if no randomized controlled trial will ever dem-
onstrate that an SVR improves liver-related survival in HCV
patients without cirrhosis, indirect evidence suggests this to be
the case, supporting SVR as an excellent marker of efﬁcacy in this
subgroup of HCV patients.Journal of Hepatology 2012Certainly
Patients with cirrhosis due to HCV are at risk of liver-related mor-
bidity and mortality [68], with annual liver-related mortality
ranging between 2% and 6%. For this reason, it is extremely sim-
pler to assess the impact of an SVR on hard clinical end points in
this population. Many studies have shown that an SVR can pro-
vide protection from development of liver-related complications,
hence improving survival of HCV cirrhotics [69–71]. Among the
ﬁrst to demonstrate a beneﬁcial impact of HCV eradication on
the natural history of patients with HCV cirrhosis were Yoshida
and colleagues, who retrospectively analyzed data from 2890
patients (337 cirrhotics) with any degree of liver ﬁbrosis, and
reported reduced annual incidence of HCC in patients with an
SVR compared to patients without an SVR (0.38 vs. 1.41), while
also demonstrating lower 5-year liver-related death rates in
those with an SVR compared to those who failed to respond to
IFN treatment (0.2% vs. 2%) [69,72]. Similarly, a prospective,
non-randomized, controlled study from Japan reported a beneﬁ-
cial impact of SVR on 271 cirrhotic patients treated with IFN and
followed-up for 7 years after treatment completion, since
patients with an SVR showed reduced rates of both HCC (11/64
vs. 73/207, 17% vs. 35%, p = 0.008) and liver-related deaths (0/
64 vs. 32/207, 0 vs. 15%, p = 0.0002) [73].
In Italy, when analyzing 920 patients with compensated cir-
rhosis who received IFN monotherapy and were followed-up
for a median period of 96 months after treatment completion,
Bruno et al. found that SVR patients had lower rates of liver-
related complications (0 vs. 1.88 per 100 person-years), HCC
(0.66 vs. 2.10 per 100 person-years) and liver-related death
(0.19 vs. 1.44 per 100 person-year) [p <0.001] compared to those
with a treatment failure [74]. Finally, two studies analyzed the
role of SVR on the clinical course of patients with advanced liver
ﬁbrosis, including not only patients with cirrhosis but those with
lower stages of ﬁbrosis, too [75,76]. Veldt and colleagues con-
ﬁrmed that an SVR was associated with a reduced risk of any
liver-related events (4/142 vs. 87/337, 3% vs. 26%, p <0.0001;
adjusted HR 0.21; 95% CI 0.07–0.58, p = 0.003), including liver
failure (0/142 vs. 42/337, 0 vs. 12%, p <0.0001; HR 0.03; 95% CI
0.00–0.91) [75]. In the study conducted by Cardoso et al., which
included 307 patients with bridging ﬁbrosis or cirrhosis fol-
lowed-up for 3.5 years after the end of treatment, incidence rates
per 100 person-years of liver-related complications, liver-related
deaths, and HCC were signiﬁcantly lower in SVR than in non-SVR
patients (0.62 vs. 4.16, 0.61 vs. 3.76 and 1.24 vs. 5.85, respec-
tively; p <0.001 for all comparison) [76].
Two Italian studies have also prospectively validated the
impact of an SVR on the clinical course of portal hypertension,
by using repeated gastroscopies in cirrhotic patients who
achieved an SVR [75,76]. Bruno and colleagues followed-up 218
patients for up to 18 years, and found SVR to be able to prevent
the development of esophageal varices (EV) (0% for SVR vs.
39.1% for non-SVR, p <0.0001) [77]. D’Ambrosio et al. found that
in 127 patients followed-up for up to 108 months after the end
of IFN-based regimens, EV development was seen in both SVR
and non-SVR patients, although the incidence of de novo EV
was reduced among patients with an SVR (3.5% vs. 15.1%,
p = 0.047) [78].
Taken together, these data clearly demonstrate the ability of
an SVR to prevent hard end points in HCV patients with advanced
ﬁbrosis/cirrhosis (Table 5), still the exact biological mechanismsvol. 57 j 1326–1335 1331
Table 4. The achievement of an SVR has an impact on extrahepatic manifestations of HCV.
Clinical event Patients Reference
SVR (+) SVR (-)
Diabetes 26/1167 (2.2%) 117/1175 (9.9%) Arase et al., 2009 [64]
Malignant lymphoma 0/2161 (0%) 25/1048 (12.6%) Kawamura et al., 2007 [65]
Improved neurocognitive functions 8/8 (100%) 0/6 (0%) Byrnes et al., 2012 [66]
Table 5. Cumulative incidence of clinical events in HCV patients with cirrhosis or advanced ﬁbrosis stratiﬁed by treatment response.
Endpoint Reference Patients SVR (+) SVR (-)
Hepatocellular carcinoma
Yoshida et al., 1999 [72] 2890 1.9% 17.9%
Shiratori et al., 2005 [73] 271 17% 35%
Bruno et al., 2007 [74] 920 5.6% 16%
Cardoso et al., 2010 [76] 307 5.8% 19.6%
Decompensation
Veldt et al., 2007 [75] 479 0% 12%
Cardoso et al., 2010 [76] 307 2.9% 13.7%
Development of esophageal varices
Bruno et al., 2010 [77] 218 0% 39%
D’Ambrosio et al., 2011 [78] 127 3.5% 15.1%
Liver-related death
Yoshida et al., 2002 [69] 2879 0.2% 2%
Shiratori et al., 2005 [73] 271 0% 15%
Bruno et al., 2007 [74] 920 1.7% 11.4%
Cardoso et al., 2010 [76] 307 2.9% 8.8%
Reviewthrough which this happens remain unclear. In theory, HCV erad-
ication may prevent development of HCC by negating the carci-
nogenetic action of HCV, which has been extensively
demonstrated in vivo and in mouse models. On the other hand,
more recent studies attribute the protective effect of an SVR on
the restoration of the pre-cirrhotic liver architecture. Recently,
two European studies have investigated the histological beneﬁts
of an SVR, whilst also assessing the clinical impact of cirrhosis
regression on the occurrence of liver-related complications
[79,80]. In the Italian-French collaborative study conducted on
38 HCV cirrhotics treated with IFN-based regimens that under-
went a post-SVR liver biopsy after a median follow-up of
61 months, an improvement in the liver architecture as assessed
by the METAVIR score was demonstrated in more than half (61%)
of the patients [80]. Interestingly, in this study a reduction in the
amount of ﬁbrosis as assessed by morphometry was demon-
strated in the near totality of the patients, even in the absence
of cirrhosis regression, once again conﬁrming ﬁbrosis to be a
dynamic process that can be positively inﬂuenced by HCV
clearance.
The study conducted by Mallet and colleagues has the added
beneﬁt of assessing the impact of cirrhosis regression, observed
in 44% of the patients, with reduction in liver-related clinical
events [79]. Indeed, while patients staged F4 after an SVR still
developed clinical events (i.e., 3 liver-related deaths/OLT, 3 HCC1332 Journal of Hepatology 2012and 1 variceal bleeding), none of the patients with cirrhosis
regression showed any liver complication. These 2 studies high-
light the histological beneﬁts of an SVR, whilst also suggesting
that occurrence of liver-related events post-SVR might actually
rely more on the architectural improvement observed in the liver
than on HCV clearance.
The clinical beneﬁts of an SVR have also been convincingly
shown in HCV patients undergoing liver transplantation for
end-stage liver disease or HCC, as recurrent HCV infection is uni-
versal in patients who are viremic at transplantation, and also
accounts for impaired post-OLT survival and increased graft loss
[81]. Successful eradication of HCV prior to OLT has been shown
to prevent recurrent infection of the graft and consequent graft
damage, most interestingly, recent studies have also shown that
if undetectable HCV RNA can be achieved by IFN-based regimens
on the liver transplant waiting list, the risk of recurrence is
reduced, with nearly 70% of patients being cured of HCV infection
post-OLT [2]. Although this is incontrovertible evidence that SVR
can positively modify survival, unfortunately, routine treatment
of HCV cirrhotics on the OLT waiting list is associated with signif-
icant side effects, increased risk of systemic infections and
increased mortality, especially if patients have decompensated
cirrhosis, thus, in this particular setting, effectively questioning
whether the theoretic efﬁcacy of a regimen actually translates
into effectiveness in clinical practice.vol. 57 j 1326–1335
JOURNAL OF HEPATOLOGY
Conclusions
Even in the absence of randomized controlled trials, there is
overwhelming evidence that surrogate end points, that are com-
monly used to assess efﬁcacy of anti-HBV or anti-HCV regimens,
are not surrogate but rather true markers of efﬁcacy as clinical
beneﬁts are associated with their achievement. The enthusiasm
for this ﬁnding is however mitigated by the fact that the efﬁcacy
of anti-HBV and anti-HCV therapies, as reported by controlled
studies, does not always translate into effectiveness once these
regimens are analyzed in the medical practice setting [82].
Although a detailed discussion of the reasons for this chasm is
beyond the scope of this article, it is important to keep in mind
that the main issues rely on under-diagnosis of chronic viral
hepatitis, as well as unequal access to treatment. It is estimated
that as few as 35% of patients with chronic HBV and only 25% of
HCV patients are aware of their disease in developed countries,
with this number obviously shrinking even more in developing
countries [83]. Even more worrisome is the fact that in Europe
and the USA, even if patients are diagnosed correctly, only 1–
16% of HBV and HCV patients are estimated to receive treatment
[84–86]. For HCV this can be partially explained by lack of
health care resources that precludes access to treatment in
some countries, and by the poor tolerability proﬁle of the cur-
rent therapeutic regimens, that unfortunately exclude from
treatment a large proportion of eligible patients. This last point
was recently magniﬁed by a study conducted at the Veterans
Affair health system in the US that showed 57% of the 82,785
HCV patients who did not receive PegIFN/RBV therapy to have
contraindications to treatment [87]. Although there is hope that
the development of an IFN-free regimen will help improve the
rate of diagnosed patients who can actually be treated with
anti-HCV regimens; up to that time, poor tolerability and
acceptability of IFN based regimens will remain a major factor
in maintaining the gap between efﬁcacy and effectiveness in
HCV patients [88,89].
For HBV infection, contraindications to treatment do not play
a major role in limiting access to treatment, as NUC therapies
are relatively adverse event free. Indeed, the major reasons for
under-treatment in the US seem to be health care cost-related
as well as patient reluctance to take long-term medication,
especially in the absence of speciﬁc symptoms. The last point
is supported by a study analyzing 1-year persistence to NUC
treatment, deﬁned as continuing acquisition of pharmacy
claims, in 11,100 patients with chronic hepatitis B [90]. Overall,
the persistence rate was 81%, and was signiﬁcantly higher in
those already on treatment (81.4%) than in those who NUC
was prescribed for the ﬁrst time (73.4%). Although the 81% per-
sistence rate can be considered acceptable, as it is actually
higher than the 1-year persistence rate to hypertensive medica-
tions and statins, it still shows that speciﬁc strategies to keep
more HBV patients on medication are needed.
In conclusion, more than 30 years from the ﬁrst introduction
of effective anti-HBV and anti-HCV treatment options [91], we
have solid treatment end points that allow us to determine the
efﬁcacy of an antiviral regimen and its ability to positively modify
the natural course of the disease. Unfortunately, we still have
quite some work ahead of us to improve diagnosis rates, ensure
equal access to therapies and develop well tolerated therapies
that will ﬁnally allow most, if not all, patients with viral hepatitis,
to beneﬁt from effective antiviral therapies.Journal of Hepatology 2012Conﬂict of interest
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